Business Context and Reporting Period
Company: MDxHealth SA (Nasdaq: MDXH)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: MDxHealth is a commercial-stage precision diagnostics company focused on urologic solutions, primarily prostate cancer testing (Confirm mdx, GPS mdx, Exo mdx) and urinary tract infection testing (Resolve mdx). The company operates CLIA-certified laboratories in the United States (California, Texas, Massachusetts) and is incorporated in Belgium.
Key Event: In September 2025, the company acquired Exosome Diagnostics, Inc. (ExoDx) from Bio-Techne, adding the Exo mdx test to its portfolio.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Revenue | $107.9 million | $90.0 million |
| Gross Profit | $69.6 million | $55.1 million |
| Gross Margin | 64.5% | 61.2% |
| Net Loss | $(33.5) million | $(38.1) million |
| Operating Loss | $(14.4) million | $(24.7) million |
| Cash and Cash Equivalents | $29.0 million | $46.8 million |
| Long-Term Debt | $76.2 million | $51.0 million |
| Accumulated Deficit | $(403.0) million | $(369.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20% year-over-year, driven by increased test volumes and the inclusion of Exo mdx revenue following the September 2025 acquisition. Tissue-based tests (Confirm mdx and GPS mdx) accounted for 76% of total revenue.
- Profitability Improvement: The operating loss narrowed by 42% to $14.4 million, and the net loss decreased by 12% to $33.5 million. Gross margin expanded by 330 basis points to 64.5% due to economies of scale.
- Expense Trends: Selling and marketing expenses rose 4% due to headcount additions from the ExoDx acquisition. General and administrative expenses increased 18%, primarily due to transaction costs and headcount expansion. Research and development expenses remained relatively flat, decreasing slightly by 2%.
- Debt and Liquidity: The company drew an additional $25 million on its OrbiMed credit facility in March 2025, bringing total outstanding borrowings to $80 million (including a subsequent $20 million draw in March 2026). Cash reserves decreased by $17.8 million, primarily due to a $28.0 million earnout payment to Exact Sciences and operating cash outflows.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and significant cash outflows expected over the next 12 months. Financial statements are prepared on a going concern basis, assuming access to additional capital.
- Debt Covenants: The company is subject to strict covenants under its $100 million OrbiMed Credit Agreement, including minimum revenue thresholds and a requirement to maintain unrestricted cash balances (initially $20 million, reducing to $5 million upon milestone achievement). Failure to meet these could trigger acceleration of debt.
- Internal Controls: Management identified a material weakness in internal control over financial reporting related to revenue accounting policies and controls over revenue accruals. Remediation efforts are ongoing.
- Acquisition Earnouts: Significant contingent liabilities exist related to the GPS mdx acquisition (Exact Sciences) and Exo mdx acquisition (Bio-Techne). A subsequent event in January 2026 amended the GPS earnout schedule, deferring payments to 2026-2028.
- Regulatory Risks: The company faces risks related to FDA regulation of Laboratory Developed Tests (LDTs), reimbursement changes by Medicare and commercial payors, and the potential loss of foreign private issuer status.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to meet the $20 million minimum cash covenant under the OrbiMed Credit Agreement given the current cash balance of $29.0 million and ongoing operating losses.
- Revenue Recognition Adjustments: Review the $3.8 million reduction in recognized revenue in 2025 resulting from a change in accounting estimate regarding collection periods (reduced from 9 to 3 months).
- Internal Control Remediation: Monitor progress on remediation of the material weakness in revenue controls to ensure future financial reporting reliability.
- Earnout Obligations: Assess the impact of the $54.5 million remaining GPS mdx earnout and $10 million Exo mdx earnout on future cash flows and potential dilution if settled in shares.
- Reimbursement Stability: Confirm the status of Medicare and commercial payer coverage for core tests (Confirm mdx, GPS mdx, Exo mdx), as these represent the majority of revenue.